Astrazeneca plc, of London, is joining forces through its Medimmune arm with the University of Texas MD Anderson Cancer Center to develop therapies that unleash patients’ immune systems to attack their cancers. The three-year agreement with Medimmune covers translational and clinical research. Terms were not disclosed.